ProCE Banner Activity

Phase II STORM Trial Part 2: Selinexor + Low-Dose Dexamethasone in Penta-Refractory MM

Slideset Download
Conference Coverage
In heavily treatment–experienced patients with triple-class penta-refractory MM, the first-in-class XPO1 inhibitor selinexor plus low-dose dexamethasone produced rapid, deep responses with manageable toxicity.

Released: December 18, 2018

Expiration: December 17, 2019

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

Celgene

Dova Pharmaceuticals

Gilead Text

Incyte

Janssen Biotech Pharmacyclics Abbvie

Jazz Pharmaceuticals, Inc.

Novartis Pharmaceuticals Corporation

Seagen

Takeda Oncology